Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04415073 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
A Phase 2 study, sponsored by Syndax Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04415073 is a Phase 2 study that was terminated before completion, run by Syndax Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT04415073, a Phase 2 study, was terminated before completion, sponsored by Syndax Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and symptoms secondary to COVID-19.
Interventions
- DRUG Placebo
- DRUG SNDX-6352
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-05-30 |
| Est. Completion | 2020-07-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04415073
The ClinicalTrials.gov registry entry for NCT04415073 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04415073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04415073 about?
NCT04415073 is a clinical study titled "A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19". This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and symptoms secondary to COVID-19.
What is the current status of trial NCT04415073?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-05-30. Estimated completion is 2020-07-13.
What interventions are being tested in trial NCT04415073?
The interventions under investigation include: Placebo (DRUG), SNDX-6352 (DRUG).
Who is sponsoring clinical trial NCT04415073?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.